Suppr超能文献

聚(D,L-乳酸)纳米粒子粒径对药物释放和与细胞相互作用的影响。

Influence of PDLA nanoparticles size on drug release and interaction with cells.

机构信息

3B's Research Group, I3Bs - Research Institute on Biomaterials, Biodegradables and Biomimetics, University of Minho, Headquarters of the European Institute of Excellence on Tissue Engineering and Regenerative Medicine, Guimarães, Portugal.

ICVS/3B's - PT Government Associate Laboratory, Braga, Portugal.

出版信息

J Biomed Mater Res A. 2019 Mar;107(3):482-493. doi: 10.1002/jbm.a.36563. Epub 2018 Nov 28.

Abstract

Polymeric nanoparticles (NPs) are strong candidates for the development of systemic and targeted drug delivery applications. Their size is a determinant property since it defines the NP-cell interactions, drug loading capacity, and release kinetics. Herein, poly(d,l-lactic acid) (PDLA) NPs were produced by the nanoprecipitation method, in which the influence of type and concentration of surfactant as well as PDLA concentration were assessed. The adjustment of these parameters allowed the successful production of NPs with defined medium sizes, ranging from 80 to 460 nm. The surface charge of the different NPs populations was consistently negative. Prednisolone was effectively entrapped and released from NPs with statistically different medium sizes (i.e., 80 or 120 nm). Release profiles indicate that these systems were able to deliver appropriate amounts of drug with potential applicability in the treatment of inflammatory conditions. Both NPs populations were cytocompatible with human endothelial and fibroblastic cells, in the range of concentrations tested (0.187-0.784 mg/mL). However, confocal microscopy revealed that within the range of sizes tested in our experiments, NPs presenting a medium size of 120 nm were able to be internalized in endothelial cells. In summary, this study demonstrates the optimization of the processing conditions to obtain PDLA NPs with narrow size ranges, and with promising performance for the treatment of inflammatory diseases. © 2018 Wiley Periodicals, Inc. J Biomed Mater Res Part A: 107A: 482-493, 2019.

摘要

聚合物纳米粒子(NPs)是开发全身和靶向药物输送应用的有力候选者。它们的尺寸是一个决定性质,因为它决定了 NP-细胞相互作用、药物装载能力和释放动力学。本文通过纳米沉淀法制备了聚(D,L-乳酸)(PDLA) NPs,其中评估了表面活性剂的类型和浓度以及 PDLA 浓度的影响。这些参数的调整允许成功生产具有定义的中等尺寸的 NPs,尺寸范围从 80 到 460nm。不同 NP 群体的表面电荷始终为负。泼尼松龙可有效包埋并从具有统计学上不同中等尺寸(即 80 或 120nm)的 NPs 中释放。释放曲线表明,这些系统能够以潜在适用于治疗炎症性疾病的适当剂量输送药物。两种 NPs 群体均与人内皮细胞和成纤维细胞具有细胞相容性,在测试的浓度范围内(0.187-0.784mg/mL)。然而,共聚焦显微镜显示,在我们实验中测试的尺寸范围内,具有 120nm 中等尺寸的 NPs 能够被内皮细胞内化。总之,本研究证明了优化加工条件以获得具有窄尺寸范围的 PDLA NPs 的能力,并且对于治疗炎症性疾病具有有前途的性能。©2018 Wiley Periodicals,Inc. J Biomed Mater Res Part A:107A:482-493,2019。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验